DaVita Inc. $DVA Shares Sold by BI Asset Management Fondsmaeglerselskab A S

BI Asset Management Fondsmaeglerselskab A S lowered its stake in shares of DaVita Inc. (NYSE:DVA) by 43.2% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 52,606 shares of the company’s stock after selling 40,035 shares during the period. BI Asset Management Fondsmaeglerselskab A S owned approximately 0.07% of DaVita worth $6,990,000 at the end of the most recent reporting period.

Several other institutional investors also recently made changes to their positions in DVA. Hantz Financial Services Inc. boosted its holdings in DaVita by 48.1% in the second quarter. Hantz Financial Services Inc. now owns 231 shares of the company’s stock valued at $33,000 after acquiring an additional 75 shares during the last quarter. Mid American Wealth Advisory Group Inc. purchased a new position in shares of DaVita in the 2nd quarter worth about $36,000. Canada Pension Plan Investment Board acquired a new position in shares of DaVita in the 2nd quarter valued at about $43,000. Ameritas Advisory Services LLC purchased a new stake in shares of DaVita during the 2nd quarter worth about $47,000. Finally, Employees Retirement System of Texas acquired a new stake in DaVita during the 2nd quarter worth approximately $49,000. 90.12% of the stock is owned by hedge funds and other institutional investors.

DaVita Price Performance

Shares of DVA stock opened at $140.77 on Friday. The company’s fifty day moving average price is $115.12 and its two-hundred day moving average price is $125.11. The firm has a market capitalization of $9.94 billion, a P/E ratio of 14.20, a P/E/G ratio of 0.52 and a beta of 0.99. DaVita Inc. has a 12 month low of $101.00 and a 12 month high of $178.38.

DaVita (NYSE:DVA) last announced its earnings results on Monday, February 2nd. The company reported $3.40 earnings per share for the quarter, beating the consensus estimate of $3.24 by $0.16. DaVita had a negative return on equity of 413.18% and a net margin of 5.47%.The company had revenue of $3.62 billion during the quarter, compared to the consensus estimate of $3.51 billion. During the same period last year, the firm earned $2.24 earnings per share. The company’s revenue was up 9.9% on a year-over-year basis. DaVita has set its FY 2026 guidance at 13.600-15.00 EPS. On average, sell-side analysts anticipate that DaVita Inc. will post 10.76 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have weighed in on DVA. Truist Financial set a $158.00 price target on shares of DaVita in a research report on Thursday. Weiss Ratings restated a “hold (c)” rating on shares of DaVita in a report on Monday, December 29th. Zacks Research upgraded DaVita from a “hold” rating to a “strong-buy” rating in a report on Wednesday. UBS Group raised their price objective on DaVita from $186.00 to $190.00 and gave the company a “buy” rating in a research report on Wednesday. Finally, Barclays upped their target price on DaVita from $143.00 to $158.00 and gave the stock an “equal weight” rating in a research report on Tuesday. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $160.50.

DaVita Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.